# IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

> **NCT07198841** · PHASE2 · RECRUITING · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 48 (estimated)

## Conditions studied

- Lung Cancer (Non-Small Cell)

## Interventions

- **DRUG:** IBI351 combined with cetuximab β

## Key facts

- **NCT ID:** NCT07198841
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-03
- **Primary completion:** 2027-09
- **Final completion:** 2028-09
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07198841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07198841, "IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07198841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*